welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.

join today!
log in

learn more

Patient Education

TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions

key information

source: Horizon Therapeutics

year: N/A

summary/abstract:

1. What is TEPEZZA?

TEPEZZA is the first and only medicine FDA-approved to treat Thyroid Eye Disease. Unlike other medicines you and your doctor may have tried, TEPEZZA treats the cause of Thyroid Eye Disease. When you have Thyroid Eye disease, a switch behind your eye, called a receptor, is turned on that causes redness and swelling. This can also make your eyes bulge. TEPEZZA is the only medicine that blocks this receptor to treat Thyroid Eye Disease at its source.

2. What is Thyroid Eye Disease?

Thyroid Eye Disease is a vision-threatening autoimmune disease that often occurs in people living with Graves’ disease; however, it is a different disease that must be managed separately. Common symptoms of Thyroid Eye Disease include double vision, bulging eyes, dry eyes, eye pain, eyelid redness and swelling, teary eyes, light sensitivity and vision changes.

3. How do I know if TEPEZZA is right for me?

If you are experiencing symptoms of Thyroid Eye Disease or have been diagnosed with the disease, you should speak with your physician about potential treatment options.

More from Teprotumumab News:

FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)

Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease

Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED

FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED

More from Teprotumumab Research:

Teprotumumab for the Treatment of Active Thyroid Eye Disease

(Authors: Raymond S. Douglas, George J. Kahaly et. al.)

Teprotumumab in the Treatment of Active TED: A Focus on Proptosis

(Author: Raymond S. Douglas)

Source: https://www.horizontherapeutics.com/PDFs/TEPEZZA-Frequently-Asked-Questions.pdf